Related Experiment Video
Updated: Jun 22, 2026
Computer Numerical Control Micromilling of a Microfluidic Acrylic Device with a Staggered Restriction for Magnetic Nanoparticle-Based Immunoassays
Published on: June 23, 2022
Multi-site analytical evaluation of a chemiluminescent magnetic microparticle immunoassay (CMIA) for sirolimus on the
Rainer W Schmid1, Johannes Lotz, Rosemarie Schweigert
1Medical University Vienna, Vienna, Austria.
Objective:
This study evaluated a new chemiluminescent magnetic microparticle immunoassay (CMIA) for sirolimus on the ARCHITECT analyzer.
Design And Methods:
Patient and laboratory proficiency samples were tested at three European sites and one site in the United States.
Results:
The CMIA total %CV's were all <8% and the Limit of Quantification (LOQ) was <1.52 ng/mL across the four sites. It cross-reacts to sirolimus metabolites F4 and F5 and showed no hematocrit interference over a range of 25% to 55%. Patient specimen correlations to three LC/MS/MS methods gave R>or=0.91 at three sites and mean biases of 14%, 25% and 39%. CMIA patient specimen correlations to the Abbott IMx gave R>or=0.94 at 2 sites and mean biases of 5.4% and 6.9%.
Conclusions:
CMIA is a precise and sensitive immunoassay method without hematocrit interference. It correlates well to both LC/MS/MS and immunoassay results, but shows an expected positive bias to LC/MS/MS.
